Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CELIM2: Neoadjuvant Cetuximab or Bevacizumab with FOLFIRI/FOLFOXIRI for Colorectal Liver Metastases
NCT01802645Phase 2Unknown
- Sponsor
- Technische Universität Dresden
- Start
- Mar 2013
- Primary completion
- Sep 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab, bevacizumab in colorectal cancer (CRC), sponsored by Technische Universität Dresden. Status: unknown.
02
Drugs
cetuximabbevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT01802645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01802645.